Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 689 participants.
Also called NCT01438814
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 689 participants
- Registry
-
NCT01438814 -
2011-002276-16
-
- Other papers using this trial's data
- Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong SAR China, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01438814. Randomized; double masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- metformin placebo
- Intervention (Drug)
- linagliptin placebo
- Intervention (Drug)
- metformin
- Intervention (Drug)
- metformin
- Intervention (Drug)
- linagliptin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01438814- Content hash
247750097bd4481c2d7ab731cec4ab4d0be3fa08dd69b3ce11b4bb2c8170bbef